News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

Kyowa Hakko Kirin News Releases 2018

December 6, 2018
Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™ (burosumab injection) for the Treatment of X-linked Hypophosphatemia (XLH) in Adults and Children
November 26, 2018
Kyowa Kirin Announces POTELIGEO® Receives Marketing Authorisation in Europe for the Treatment of Mycosis Fungoides and Sézary Syndrome
November 22, 2018
GSK and Kyowa Hakko Kirin sign strategic commercialisation deal in Japan for daprodustat, a potential new oral treatment for anaemia associated with chronic kidney disease
November 5, 2018
MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan
November 2, 2018
Kyowa Hakko Kirin Announces a Phase 1 Clinical Study of its IDO inhibitor in solid tumor, under a collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer
October 30, 2018
New window opensAnnouncement of Consolidated Financial Results Fiscal 2018 Third Quarter
September 21, 2018
Kyowa Kirin Announces Mogamulizumab Received Positive CHMP Opinion for the Treatment of Mycosis Fungoides and Sézary Syndrome
September 21, 2018
Kyowa Hakko Kirin Selected for Inclusion in Stock Indices GPIF Selected, FTSE4Good Index, and MSCI ESG Leaders Indexes
September 20, 2018
Mylan and Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization for Hulio®, Biosimilar AdalimumabPDF file:New window opens(148KB)
September 5, 2018
Renaming of Kyowa Hakko Kirin (Singapore) Pte. Ltd.
August 21, 2018
Kyowa Hakko Kirin Receives the Partial Change Approval of POTELIGEO® in Japan
August 20, 2018
Kyowa Hakko Kirin Announces Results of Early Phase 2 Trial of KW-6356 for Parkinson's Disease at IAPRD
August 16, 2018
Kyowa Hakko Kirin Announces Approval of Darbepoetin Alfa Injection Syringe[KKF] in Japan
August 9, 2018
Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome
July 31, 2018
New window opensAnnouncement of Consolidated Financial Results Fiscal 2018 Second Quarter
July 31, 2018
Notice Regarding Change of Trade Name, Partial Amendments to the Articles of Incorporation, and Change of Location of Head OfficePDF file:New window opens(60KB)
July 31, 2018
Kyowa Hakko Kirin Submits Application for Additional Indication for Romiplostim (Recombinant) for Aplastic Anemia in Japan
July 27, 2018
Mylan and Fujifilm Kyowa Kirin Biologics Announce Positive CHMP Opinion for Hulio™, Biosimilar AdalimumabPDF file:New window opens(156KB)
June 4, 2018
Kyowa Kirin Presents New Data for Mogamulizumab from Its Lead Program in Cutaneous T-cell Lymphoma (CTCL) at ASCO
May 31, 2018
Kyowa Hakko Kirin Initiated Phase 3 Clinical Study of Bardoxolone Methyl (RTA 402) for Diabetic Kidney Disease
May 30, 2018
Kyowa Hakko Kirin Announces FDA Notification of PDUFA Action Date Extension for Mogamulizumab
May 24, 2018
Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of MedicinePDF file:New window opens(204KB)
May 22, 2018
Kyowa Hakko Kirin Launches ORKEDIA® TABLETS (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan
May 17, 2018
Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)
May 8, 2018
New window opensAnnouncement of Consolidated Financial Results Fiscal 2018 First Quarter
May 7, 2018
Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in the U.S. for the Treatment of X–linked Hypophosphatemia (XLH) in Children and Adults
April 18, 2018
Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza) for the Treatment of Children and Adults with X–Linked Hypophosphatemia (XLH)
April 11, 2018
Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize Biosimilar to Humira® (adalimumab)PDF file:New window opens(66KB)
March 30, 2018
Matters concerning controlling shareholdersPDF file:New window opens(66KB)
March 28, 2018
Bardoxolone Methyl (RTA 402) Designated for the Treatment of Diabetic Kidney Disease under the Priority Review and Designation System by the Ministry of Health, Labour and Welfare
March 23, 2018
Notice regarding allotment of stock acquisition rights (stock compensation-type stock options)PDF file:New window opens(20KB)
March 23, 2018
Kyowa Hakko Kirin Receives Approval for ORKEDIA® Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan
March 22, 2018
Kyowa Hakko Kirin and BioWa Obtain Successful Settlement of United States Patent Infringement Lawsuit against Aragen Bioscience and TransposagenPDF file:New window opens(34KB)
February 23, 2018
Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives ConditionalMarketing Authorisation in Europe for the Treatment of X–Linked Hypophosphatemia in Children
February 21, 2018
Notice regarding stock acquisition rights for stock compensation-type stock optionsPDF file:New window opens(61KB)
February 21, 2018
Notice Concerning Change of Certified Public Accountant etcPDF file:New window opens(36KB)
February 8, 2018
New window opensAnnouncement of Consolidated Financial Results Fiscal 2017
January 29, 2018
Kyowa Hakko Kirin Announces the Establishment of a Regional Headquarters Function for the Asia and Oceania Region in SingaporePDF file:New window opens(137KB)
January 29, 2018
Kyowa Hakko Kirin Announces Reorganization of Research and Development DivisionPDF file:New window opens(396KB)
January 29, 2018
Kyowa Hakko Bio Announces a Change to the Representative DirectorPDF file:New window opens(68KB)
January 4, 2018
Notice Concerning Completion of Consolidated Subsidiary Share Transfer (Report on Progress of Matters Disclosed)PDF file:New window opens(65KB)

Get Adobe® Reader®You need Adobe® Reader® to view these documents.
Download Adobe® Reader® of Adobe Systems here.



To Page Top